Interaction effect of serum 25-hydroxyvitamin D levels and CYP1A1, CYP1B1 polymorphisms on blood pressure in an elderly population

Park, Hye Y.; Kim, Jin Hee; Bae, Sanghyuk; Choi, Yi Young; Park, Jae Young; Hong, Yun–Chul

doi:10.1097/hjh.0000000000000381

Cited by 16 publications

(10 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is evidence linking CYP17 polymorphisms and estrogen synthesis variability which in turn may increase the risk for cancer [6,7,25], osteoporosis [26], Alzheimer disease [27], and also cardiovascular disease through the atherogenic process [28][29][30]; our data adds to the prior, however linking for the first time the studied CYP polymorphism with the intensity of mood symptoms in postmenopausal women. Clearly, all these conditions are steroid hormone and age-related in which genetic background may have a pivotal role over disease development and outcomes.…”

Section: Discussionsupporting

confidence: 47%

Increased mood symptoms in postmenopausal women related to the polymorphism rs743572 of the CYP17 A1 gene

Loja-Chango

Pérez‐López

Simoncini

et al. 2016

Gynecological Endocrinology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 47%

Increased mood symptoms in postmenopausal women related to the polymorphism rs743572 of the CYP17 A1 gene

Loja-Chango

Pérez‐López

Simoncini

et al. 2016

Gynecological Endocrinology

View full text Add to dashboard Cite

show abstract

“…Recent studies have shown an association between BP circulating levels of 25(OH)D 28 as well as with genetic variations in CYP1A1 and CYP1B1. 29 While both studies have shown an association of 25(OH)D with systolic and diastolic BP, a stronger correlation was seen between 25(OH)D and diastolic BP. These findings need to be further explored in a prospective longitudinal study.…”

Section: Raas Blockade Increases S-klotho Levelsmentioning

confidence: 95%

Normal 25-Hydroxyvitamin D Levels Are Associated with Less Proteinuria and Attenuate Renal Failure Progression in Children with CKD

Shroff

Aitkenhead

Costa

et al. 2016

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Proteinuria and hypertension are major determinants of CKD progression and contribute to glomerulosclerosis, interstitial inflammation and progressive renal scarring, which are mediated, in part, through activation of the renin-angiotensin-aldosterone system (RAAS). 1 Decreasing proteinuria, regardless of its cause, is beneficial in slowing progressive loss of renal function. 2,3 Clinical trials of proteinuric chronic nephropathies indicate that RAAS inhibition with angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) can attenuate CKD progression, 2-4 yet there

show abstract

“…Many observational studies have reported an inverse association between low VitD levels and brachial BP in large samples from the general population [23,24,25], but also among Peruvian adolescents [26], middle-aged individuals [27], people aged >60 years and the elderly [28,29], pregnant women and women aged 20-80 years [30,31]. Similarly, the evidence from medium to large observational studies shows strong and independent inverse associations between serum VitD and cfPWV among diverse study populations [32,33,34,35,36,37,38].…”

Section: Summary Of Observational Data On the Relationship Between Sementioning

confidence: 99%

Effectiveness of Vitamin D Supplementation for Cardiovascular Health Outcomes

Veloudi

Jones

Sharman³

2016

Pulse

View full text Add to dashboard Cite

There is a plausible physiological theory, supported by many observational studies, that vitamin D supplementation should be effective for improving cardiovascular end points, such as blood pressure (BP), large artery stiffness, atherosclerosis, endothelial function and clinical events. However, results from randomised controlled trials (RCTs) have been inconsistent. In this review, we evaluated the evidence regarding the effectiveness of vitamin D supplementation for cardiovascular surrogate and hard clinical end points. RCTs were assessed in terms of sample size, duration of supplementation, baseline vitamin D level inclusion criteria (i.e., absence of vitamin D deficiency), dosage of vitamin D and population under investigation. Forty-five RCTs were identified. Eight RCTs with BP and 6 RCTs with large artery stiffness as the end points were found to comply with guidelines for the optimal design of clinical trials evaluating nutrient effects. Only 2 of the RCTs with an optimal design were effective in decreasing BP with vitamin D supplementation, although these were of moderate sample size (<150) and very short duration (8 weeks for both), whilst no RCT was effective in reducing large artery stiffness. Similar results were observed for atherosclerotic and endothelial function markers as end points. Only 1 RCT reported cardiovascular events as an end point and found neither increased nor decreased incident cardiovascular events over 7 years of follow-up. In conclusion, results from published RCTs indicate that vitamin D supplementation is ineffective in improving cardiovascular health among various patient populations, including in the presence or absence of vitamin D deficiency.

show abstract

Interaction effect of serum 25-hydroxyvitamin D levels and CYP1A1, CYP1B1 polymorphisms on blood pressure in an elderly population

Abstract: Genetic variations in CYP1A1 and CYP1B1 and the serum levels of 25(OH)D showed synergistic effect on BP, especially in individuals currently in treatment for hypertension.

Cited by 16 publications

References 53 publications

Increased mood symptoms in postmenopausal women related to the polymorphism rs743572 of the CYP17 A1 gene

Increased mood symptoms in postmenopausal women related to the polymorphism rs743572 of the CYP17 A1 gene

Normal 25-Hydroxyvitamin D Levels Are Associated with Less Proteinuria and Attenuate Renal Failure Progression in Children with CKD

Effectiveness of Vitamin D Supplementation for Cardiovascular Health Outcomes

Contact Info

Product

Resources

About